Sun announces positive results of phase-3 clinical trials

Sun Pharmaceutical Industries today said results of two phase-3 clinical trials, evaluating the efficacy of a new molecule being developed to treat psoriasis, have been positive.
"Two pivotal phase-3 clinical trials evaluating the efficacy and safety of the investigational IL-23p19 inhibitor antibody tildrakizumab (MK-3222) in patients with moderate-to-severe plaque psoriasis met their primary endpoints for both evaluated doses," Sun Pharma said in a statement.
Tildrakizumab is the first IL-23p19 inhibitor to demonstrate positive results in phase-3 clinical trials for the treatment of moderate-to-severe plaque psoriasis, Sun Pharma Managing Director Dilip Shanghvi said.
"We are encouraged by these results and the potential to provide a new treatment option to patients with moderate-to-severe plaque psoriasis, a disease that often takes both a physical and emotional toll on their lives," he added.

Over 1,800 patients at more than 200 clinical sites participated in the clinical trials, Shanghvi said.
The Mumbai-based firm said it is now going ahead with preparations for submission of a biologics licence application to the US Food and Drug Administration.
The detailed findings from the phase-3 clinical trials will be presented at upcoming scientific meetings, it added.
Shares of Sun Pharma today ended at Rs 802.75 apiece on the BSE, up 0.55 per cent from previous close.